SCHEMBL30318005

SCHEMBL30318005

C[C@H]1[C@@H](C)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGES2 Q9H7Z7 9/20 0.76
ALDH1A1 P00352 4/20 0.76
LMNA P02545 3/20 0.76
HTT P42858 3/20 0.76
CYP3A4 P08684 2/20 0.76
TP53 P04637 1/20 0.76
SMN1; SMN2 Q16637 1/20 0.76
CYP1A2 P05177 2/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C19 P33261 1/20 0.59
HIF1A Q16665 1/20 0.59
NR1I2 O75469 1/20 0.59
CYP2B6 P20813 1/20 0.59
GAA P10253 1/20 0.59
HPGD P15428 1/20 0.59
HSD17B10 Q99714 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL67483 1.00 PTGES2 (0.76) PTGES2ALDH1A1LMNAHTTCYP3A4
SCHEMBL19342809 1.00 PTGES2 (0.76) PTGES2ALDH1A1LMNAHTTCYP3A4
SCHEMBL14458620 1.00 PTGES2 (0.76) PTGES2ALDH1A1LMNAHTTCYP3A4
SCHEMBL13390418 1.00 PTGES2 (0.76) PTGES2ALDH1A1LMNAHTTCYP3A4
SCHEMBL15243262 1.00 PTGES2 (0.76) PTGES2ALDH1A1LMNAHTTCYP3A4
SCHEMBL14013807 1.00 PTGES2 (0.76) PTGES2ALDH1A1LMNAHTTCYP3A4
SCHEMBL13934375 1.00 PTGES2 (0.76) PTGES2ALDH1A1LMNAHTTCYP3A4
SCHEMBL14013803 1.00 PTGES2 (0.76) PTGES2ALDH1A1LMNAHTTCYP3A4
SCHEMBL13390262 0.87 PTGES2 (0.58) PTGES2ALDH1A1LMNAHTTCYP3A4
Artenimol SCHEMBL23843510 0.86 PTGES2 (1.00) PTGES2ALDH1A1LMNAHTTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230094952-A1 Method for Culturing Hematopoietic Stem Cells Sumitomo Pharma Co., Ltd. (JP) 2023-03-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230094952-A1 Method for Culturing Hematopoietic Stem Cells HCLS1, KIT, MCL1 PTGES2 3102/4885ALDH1A1 16/4885LMNA 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.